CanadaTeva Canada’s Octreotide for injectable suspension (10 mg DIN 02503751, 20 mg DIN 02503778, 30 mg DIN 02503786) in the listed lot numbers is affected; check your vial/kit against the lot numbers provided. The recall was issued because of quality concerns related to deficiencies in Good Manufacturing Practices (GMP). If you have an affected product, do not use it, speak to your health care professional for an alternative or replacement, return it to the pharmacy for disposal, and seek medical attention for signs of infection or other unexpected symptoms; contact Teva Canada with questions.
What's being recalled
Depth of recall: End users
Companies: Teva Canada Limited, 30 Novopharm Court, Unit A,, Toronto, ON, M1B 2K9, Canada.
How to identify it
Brand: Teva Canada Ltd.; Product Name: Octreotide for injectable suspension 10 mg/vial; Market Authorization: DIN 02503751; Dosage Form: Kit, Powder For Suspension, Sustained-Release; Strength: Octreotide acetate 10 mg/vial; Lot Number: 4401203R, 4401202, 4400915
Brand: Teva Canada Ltd.; Product Name: Octreotide for injectable suspension 20 mg/vial; Market Authorization: DIN 02503778; Dosage Form: Kit, Powder For Suspension, Sustained-Release; Strength: Octreotide acetate 20 mg/vial; Lot Number: 4501460, 4401309, 4401501, 4401231, 4401065
Brand: Teva Canada Ltd.; Product Name: Octreotide for injectable suspension 30 mg/vial; Market Authorization: DIN 02503786; Dosage Form: Kit, Powder For Suspension, Sustained-Release; Strength: Octreotide acetate 30 mg/vial; Lot Number: 4501296, 4401394, 4500804, 4500219, 4401208, 4500218, 4401207, 4400955, 4400918
The hazard
Quality concerns of affected lots due to deficiencies in Good Manufacturing Practices (GMP).
What to do
If you have an affected product, do not use it. Speak to your health care professional immediately to obtain an alternative or replacement product. If you are unsure whether your product is affected, check with your pharmacy.
Seek medical attention if you have used this product and are experiencing symptoms of infection, or other unexpected symptoms or side effects.
Return affected product(s) to the pharmacy where it was purchased for proper disposal.
Consult a health care professional if you have used the affected product and have health concerns.
Contact Teva Canada Limited by calling toll-free at 1-800-268-4127, option 3, or by email at druginfo@tevacanada.com, if you have questions about this recall.
Report any health product-related side effects or complaints to Health Canada.
The official notice
This page is a summary of the notice published by Health Canada, collected from Health Canada, CFIA and Transport Canada. Check the original before you act on it.
Read the official notice (opens in a new tab)